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1. Introduction 
Hepatitis-C-virus (HCV) represents one of the most serious threats for human liver and 
chronic HCV-infection results in the development of liver cirrhosis and hepatocellular 
carcinoma (HCC). HCV is an enveloped RNA-virus belonging to the flaviviridae family. 
Currently six identified HCV-genotypes, different in their geographic distribution define the 
severity of pathogenic effect, disease course and treatment results. About 1.5% of the 
European population are HCV-positive. Although the natural history of HCV-infection is 
rather slow, highly variable disease progression may lead to a rapid loss of liver function  
[1, 2]. An estimated annual incidence of new infections (3-4 millions) explains 170 million 
HCV-positive people worldwide. 80% of all HCV-infections become chronic and fewer than 
25% of HCV-positive individuals are clinically apparent presenting either in a clinically 
stable state with few only symptoms or with fully decompensated liver disease with a dire 
prognosis [1, 3, 4]. Once chronic HCV-infection is established, the rates of spontaneous viral 
clearance remain discouraging. 
The development of liver fibrosis is the main determinant of morbidity and mortality of 
HCV-positive patients [1]. Fibrosis results from excessive formation of extracellular matrix 
(ECM). The established imbalance of fibrogenesis and fibrolysis during chronic liver 
damage, which leads to scarring of the liver, is accompanied by a progressive loss of liver 
function despite the use of antiviral or anti-inflammatory agents [1, 5]. HCV-re-infection can 
trigger the excess synthesis and deposition of ECM usually by activation of cytokine release 
[1, 5]. Activated macrophages, lymphocytes, bile duct epithelia but also endothelia and 
myofibroblasts are sources of fibrogenic cytokines and growth factors that can stimulate 
hepatic stellate cells HSCs to produce ECM-molecules leading to fibrosis during chronic 
liver injury [1, 5]. The most prominent fibrogenic cytokine seems to be the transforming 
growth factor-β1 (TGF-β1), which is released during inflammation, tissue regeneration and 
fibrogenesis. TGF-β1 is considered to play a pivotal role in the hepatic fibrogenesis strongly 
increasing the production and deposition of ECM-components [1, 6]. Fibrosis progression is 
influenced by a whole range of virus, host and environmental factors. Advanced age, male 
gender, race (black), viral co-infection (HBV), alcohol intake and genetic background seem 
to influence the course of the disease [7-10]. For patients with HCV-induced end-stage liver 
disease (ESLD) liver transplantation (LT) remains the treatment of choice according to 
functional (cirrhosis CHILD B-C) or neoplastic (HCC) severity of hepatic injury [11]. 30-50% 
of all LTs are performed due to HCV-associated ESLD thus representing one of the leading 
LT-indications. 
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Regarding the recurrence of pre-transplant diseases after LT, HCV-re-infection may 
represent one of the most important threats to graft and patient survival after primarily 
successful transplantation. Although remarkable differences in the course of HCV-infection 
exist between pre- and post-transplant settings, the uniform picture of liver or graft cirrhosis 
is similar and comparable to a certain extent. 
2. HCV-recurrence after liver transplantation 
HCV-recurrence after LT is one of the most important issues regarding the spectrum of 
current graft diseases. Despite comparable pathophysiological processes, the course of graft 
hepatitis is usually more progressive compared to the natural setting of HCV-infection [11-15]. 
2.1 Epidemiological and etiological aspects 
Most of the patients either show biochemical or histological signs of inflammation, whereas 
30% of all graft recipients develop graft cirrhosis within 5 years after LT, leading to an 
impaired patient survival and a dubious transplant success. Progressive loss of graft 
function may even require re-transplantation despite of consistent antiviral treatment [16]. 
Arbitrary in use and manifold in extent, the term “HCV-recurrence” implies the whole 
spectrum of graft disease such as asymptomatic infection, graft-hepatitis, fibrosis and 
eventually transplant cirrhosis. The uniform picture of end stage graft disease comprises 
scar formation and replacement of liver parenchyma by connective tissue as a result of 
accelerated fibrogenesis [1, 17, 18]. Clinical presentation of graft function loss is very similar 
to the natural setting though more rapid and progressive. Ascites, variceal bleeding, 
encephalopathy and jaundice are common results of graft decompensation. 
Patient survival with HCV-recurrence is dramatically compromised compared to non-HCV-
related transplants [15]. Several studies pointed out significantly lower survival rates in 
HCV-positive recipients due to accelerated fibrosis development. Survival analysis 
performed in a cohort of 2294 patients (Charité, Berlin, Germany since 1988) demonstrated 
highly significant differences (unpublished data) comparing 455 HCV-positive to 1839 HCV-
unrelated transplants (p<0.001; fig.1). 
 
Fig. 1. Disease-related post-transplant survival 
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Persisting in the extrahepatic reservoir, HCV reappears as a universal post-transplant 
phenomenon, leading to the development of graft disease in a highly variable manner. At 
the moment of hepatectomy HCV-load may become even undetectable indicating the 
importance of the liver as major HCV-reservoir. After transplantation, HCV-redistribution 
arises from extrahepatic sources (lymphatic tissue) and HCV-viremia reappears within first 
post-transplant days [19, 20]. Molecular analysis has shown that postoperative viral strains 
are identical to those detected before transplantation. HCV-load literally explodes after one 
week achieving values of one logarithmic step higher compared to pre-transplant condition 
basically due to indispensable immunosuppressive medication [21]. Among currently 
known genetic HCV-variants (1-5), genotype-1b predominates in the post-transplant setting 
due to selection as the most stubborn [22]. 
2.2 Diagnostics 
HCV-recurrence, ranging from asymptomatic viremia to rapid fibrosis progression requires 
an exact description and diagnostic assessment of injury extent. Clinical presentation of 
HCV-recurrence is frequently unspectacular, basically corresponding to HCV-infection in 
the natural setting. Though highly variable and unreliable, general discomfort and fatigues 
may appear as first symptoms of HCV-recurrence. In contrast, advanced stages may 
clinically result in jaundice, hemorrhage, edema, ascites, encephalopathy, infection, 
secondary organ failure according to the degree of functional deterioration. Therefore, 
standardized quantification of graft damage and disease extent must be performed, in order 
to identify high-risk-patients, initiate antiviral treatment and monitor further development. 
2.2.1 Clinical and biochemical aspects 
After successful LT, graft function is usually followed-up according to local protocols. 
Clinical presentation after LT is usually unremarkable unless advanced graft disease has 
already developed and symptoms of liver insufficiency become apparent [21]. Elevated 
aminotransferases (2-4-fold) are frequently observed along with normal parameters of 
synthesis and excretion as a biochemical expression of inflammatory activity in 
parenchyma. Severe HCV-recurrence may lead to variably impaired detoxification and 
synthesis similar to the natural course of HCV-associated liver disease [16]. However, the 
differentiation of HCV-associated graft hepatitis from acute cellular rejection (ACR) is 
frequently impossible, based on laboratory data, only. Taken a sufficient level of 
immunosuppression and a detectable HCV-load, HCV-recurrence seems to be probable 
after the exclusion of immunological, metabolic, vascular and biliary causes for biochemical 
abnormalities. Therefore, graft biopsy must urgently be performed as diagnostic gold 
standard [21]. 
2.2.2 Histology 
As a very reliable method, histological analysis of graft tissue usually helps to determine the 
etiology of graft malfunction especially in combination with supportive results of other 
paraclinical examinations such as laboratory analysis, cholangiography and Doppler-
sonography. The histological picture of HCV-re-infection usually implies a mild sinusoidal 
infiltration by lymphocytes and mononuclear cells resulting in a variable degree of portal 
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inflammation. HCV-associated inflammation may trigger an excessive synthesis of ECM-
components and result in the accumulation of collagens. 
The imbalance between synthesis and degradation of connective tissue defines the 
progression of fibrosis [1]. Once the diagnosis of HCV-related graft hepatitis is made, the 
indication to antiviral treatment should be evaluated in order to prevent aggravation. The 
development of fibrosis is not linear [21, 23]. Since the accumulation of connective tissue and 
pathologic alteration of histological structure are definitive endpoints of HCV- recurrence, 
serial biopsies and long-term follow-up are highly indispensable for the assessment of HCV-
related damage (fig. 2) [21, 24, 25]. 
 
Fig. 2. Post-transplant dynamics of fibrosis 
Along with several available and currently accepted scores, hepatic fibrosis is frequently 
characterized by a semiquantitative score, proposed by Scheuer & Desmet [26]. Using a scale 
(0-4), fibrosis is staged as ordinal data values (0: absent, 1: mild without septa, 2: moderate 
with few septa, 3: numerous septa without cirrhosis and 4: cirrhosis). Although no 
arithmetic procedures can be performed with ordinal data, Desmet and Scheuer-score 
appears to be superior in reproducibility over other semiquantitative systems in fibrosis 
assessment [27]. In a recent analysis according to Desmet and Scheuer, accepted time-related 
rates of graft cirrhosis development (30% after 5 and 50% after 10 years) could be confirmed 
in a representative cohort of more than 400 transplants with HCV-recurrence (Charité, 
Berlin, Germany). Advanced fibrosis stages (3-4) were observed in 39.2% after 5 and 47.5% 
after 10 post-transplant years, respectively, emphasizing the importance of a universal term 
definition (fig. 3). 
Apart from fibrosis quantification, microscopic evaluation of inflammatory pattern helps to 
differentiate severe cellular rejection from HCV-infection in spite of significant biochemical 
similarities [28]. Low levels of immunosuppression may induce an ACR-event. Due to 
frequently simultaneous occurrence of acute cellular rejection and HCV-re-infection in the 
early post-operative period, these entities tend to be easily misdiagnosed. Classified according 
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to Banff-criteria, ACR may present microscopically as an accumulation of mononuclear cells 
(lymphocytes, eosinophil and neutrophil granulocytes) including endothelitis, portal, 
centrolubular inflammation and biliary alterations [28]. 
 
Fig. 3. Progression to advanced fibrosis stages 
Currently ACR is treated by the application of intravenous steroid pulses for 3-5 days. In 
few cases, mono- or polyclonal antibodies are administered in case of steroid resistant 
rejection [21]. HCV-exacerbation is widely accepted as an inevitable side effect of ACR-
treatment due to limited alternatives. Morphologically, mild forms of ACR hardly differ 
from HCV-re-infection due to principal differences in the pathogenesis. Regarding the 
danger of steroid-associated HCV-exacerbation, steroid-based treatment is recommended in 
moderate and severe degrees of ACR in HCV-positive transplants according to current 
standards. In contrast, mild ACR should be treated by the administration of higher 
calcineurin inhibitor doses (CNIs) and MMF-complementation as dual immunosuppressive 
medication. Therefore, the diagnosis must be based on the histological analysis of graft 
biopsy as most reliable method [21, 27]. 
3. Risk factors 
The progression of HCV-associated graft disease is influenced by a whole range of virus, 
donor, recipient and environmental factors. The variety of relevant confounders exhibiting 
variable impact, their interaction in genetically unique living individuals resulting from a 
successful LT have been in the center of attention for many decades. Some risk factors for 
the development of graft fibrosis have been identified during the scientific attempt to 
unravel the mystery and to understand the substance of HCV-recurrence in detail [21, 29]. 
However, the majority of observations were based on low sample size. Nevertheless, the 
existence of virological, immunological, surgery-related and even historical confounders 
illustrates the complexity and variability of the issue (table 1). 
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Variables  
age >50 years 
warm and cold ischemia long ischemia 
organ quality steatosis, iron concentration 
donor 
and  
surgery  
genetics IL28B 
age older age 
gender male 
race black 
host  
genetics IL28B, TGF-β1 
blood group mismatch 
histocompatibility mismatch 
immunosuppression type, high levels 
ACR-episodes ACR-occurence 
ACR-treatment corticosteroids, OKT-3 
immunology 
co-infection CMV 
genotype Ib 
HCV-related 
viremia level early peak 
antiviral treatment non-response pre- and post-transplant 
Table 1. Variables related to the severity of HCV-recurrence 
3.1 Donor- and surgery-related factors 
Liver graft has been quickly suspected to affect HCV-recurrence as a dominant location of 
pathologic events. Several studies detected a negative effect on HCV-recurrence regarding 
donor age, organ quality, histocompatibility matching, steatosis and iron concentration [30, 
31]. Furthermore, transplant-related factors such as duration of organ harvesting, warm and 
cold ischemia time (transport and implantation) have been shown to contribute to HCV-
related post-transplant events and processes [21]. Genetic variance of growth factors and 
cytokines in donor is currently suspected to impact on the progression and treatment of 
HCV-associated graft disease [32, 33]. 
3.2 Host-related factors 
The development of fibrosis seems to be twice as fast in males compared to female 
recipients. In contrast to the controversially discussed role of recipient age, black race and 
male gender have been shown to negatively affect fibrosis progression [22]. Cytokines and 
growth factors are final effectors in the pathogenesis and may theoretically play a key role in 
fibrogenesis [1, 34]. Analogously to donor, genetic polymorphisms of recipient cytokines are 
being currently intensively investigated and seem so far to modulate the course of HCV-
recurrence and antiviral treatment success. This issue will be presented below. 
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3.3 Viral factors 
The impact of viral properties on the course of HCV-associated graft disease has been 
assessed by several studies, obtaining partially controversial results. Progression of graft 
hepatitis-C seems to be accelerated in patients with HCV-genotype-Ib, high pre-transplant 
HCV-RNA-load and early post-transplant peak of viremia [29, 35-37]. Interestingly, HCV-
core protein has been demonstrated to promote inflammation by the release of oxidative 
stress and to reinforce apoptosis and steatosis. During inflammation, activated hepatic 
stellate cells generate ECM-components and determine the rate of graft fibrosis progression. 
Furthermore, CMV-coinfection seems to reinforce fibrosis progression [25, 36]. 
3.4 Immunologic factors 
Along with histocompatibility mismatch, mode of immunosuppression, the occurrence of 
acute cellular rejection and its treatment have been identified as dominant confounders of 
HCV-related graft disease [21, 22]. 
3.4.1 Immunosuppressive medication 
Highly complicated interaction and vulnerable balance in the immune answer to HCV is 
compromised by the inevitable use of immunosuppressive medication. The inappropriate  
T-cell mediated response to HCV-re-infection is accused to be responsible for disease 
progression. Stronger immunosuppressive regimen may accelerate fibrosis progression [38, 
39]. Calcineurin-inhibitors (cyclosporine and tacrolimus) represent the backbone of current 
immunosuppressive medication and have been suspected to influence the extent of HCV-
recurrence. In spite of similar pharmacological mechanisms, cyclosporine has been proposed 
to have a positive effect on interferon-based antiviral treatment. However, clinical 
significance currently remains unclear [40]. Levels of HCV-viremia seem to be the CNI-type 
[41]. 
Mycophenolate mofetil (MMF) inhibits the lymphocyte proliferation and may decrease the 
overall inflammatory activity in the graft. MMF was strongly suspected to have a positive 
impact on fibrogenesis [42]. However, the theoretically promising antiviral effect of MMF 
in-vitro could not be demonstrated as substantial, regarding fibrosis development. 
Nevertheless, dual immunosuppression based on CNIs and MMF is frequently used in 
patients with HCV-recurrence and is believed to exhibit a positive effect on the severity of 
HCV-recurrence [42]. 
Sirolimus as a representative of mTOR-inhibitors seems to decelerate fibrosis progression in 
graft re-infection by blocking post-receptor signal transduction and interleukin-2-dependant 
proliferation. Although, no definite statement can currently be made, sirolimus may 
represent a reasonable therapeutic option [43, 44]. 
3.4.2 Acute cellular rejection 
The occurrence of acute cellular rejection (ACR), its severity and frequency have been 
reported to aggravate the course of HCV-related graft disease [16]. Administration of 
corticosteroid pulses and antibodies (OKT-3) in case of steroid-resistant rejection as ACR-
therapy are associated with a significant elevation of viral load and accelerated fibrosis 
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development [21, 22]. The extent of immunosuppression, CNI-type and previous episodes of 
rejection are widely considered to affect the incidence of ACR. Furthermore, individually 
different genetic background of ACR-mediating cytokines might be involved in the 
pathogenesis [45]. Furthermore, individually different genetic background of ACR-
mediating cytokines might be involved in the pathogenesis [45]. Mannose-binding-lectin-2 
(MBL-2) plays an important role in the innate immune system acting as opsonine by 
activation antibody-independent pathway of the complement system [46, 47]. 
Polymorphisms of MBL-2-gene (rs7096206; G/C) have been shown to affect the occurrence 
of ACR in a homogenous cohort of HCV-re-infected patients (Eurich et al). 
3.5 Antiviral therapy 
Antiviral therapy is the cornerstone of graft cirrhosis prevention in HCV-infected recipients. 
The clinical and histological course of hepatitis-C is inseparably associated with antiviral 
treatment strategies. Recent introduction of new formulations of interferons (IFN) such as 
pegylated interferons (PEG-IFN) in the treatment of HCV-infection before and after LT 
revealed promising results. Application of pegylated interferon 〈-2a and ribavirin (RBV) 
provide a sustained virologic response (SVR) in 40-50% of all treated cases with HCV-
genotype 1 and in 80% with genotypes 2 or 3. In post-transplant setting, the success of 
antiviral therapy is significantly lower, and only a maximum of 30-40% of all patients 
achieve SVR [21, 39]. Some evidence exists that IFN/RBV-treatment may prevent graft 
cirrhosis even in unsuccessfully treated patients. Interestingly, fibrosis progression may 
occur in spite of successful IFN-based antiviral treatment [48]. Hence, this issue remains 
controversial. Moreover, immunologically active IFN may trigger rejection (5-6%) and 
induce chronic rejection processes during the antiviral treatment [12, 49]. 
3.6 Genetic diversity 
HCV-re-infection can trigger the excess synthesis and deposition of ECM usually by 
activation of cytokine release. Activated macrophages, lymphocytes, bile duct epithelia but 
also endothelia and myofibroblasts are sources of fibrogenic cytokines and growth factors 
that can stimulate hepatic stellate cells HSCs to produce ECM-molecules leading to fibrosis 
during chronic liver injury [50, 51]. Genetic polymorphisms of enzymatic systems, cytokines 
and growth factors which are involved in the process of immunomodulation, inflammation, 
ECM-turnover and anti-oxidative stress defense, may explain the widely different 
individual extent of HCV-induced graft damage [52-54]. Highly variable rates of functional 
impairment defined by inflammation, tissue remodeling but also antiviral capabilities and 
antiviral therapy response suggest the existence of endogenous risk compounds both in 
natural and post-transplant settings of the disease [33]. The maximal capacity to produce 
different levels of cytokines in response to noxious stimulation has been shown to be under 
genetic control and differs among liver graft recipients [32, 55]. Genetically different 
backgrounds in transplant population, consisting of donor and recipient, may differently 
contribute to disease development. Although the exact mechanism is not yet understood in 
detail both, donor and recipient genetics may interact. The expression of disease-related 
effectors may be individual, time and tissue dependant [56]. Therefore, the interaction 
between two different individual backgrounds may theoretically influence post-transplant 
processes in the graft and be therefore pathogenetically relevant [57]. 
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3.6.1 Genetic variants in donor 
The ability to produce different levels of cytokines in response to stimulation is suspected to 
be gene-associated [58]. Liver graft is usually colonized by recipient cell populations such as 
endothelia and lymphatic tissue thus theoretically forming a functional chimerism of donor 
and recipient regarding biochemical processes [56, 59]. Furthermore, the impact of genetic 
differences in donor and recipient may vary according to the duration of post-transplant 
follow-up [57]. Results of intensive investigations demonstrated that donor polymorphisms 
of IL-28B-gene may partially predict the outcome of antiviral treatment [60]. 
3.6.2 Genetic variants in recipient 
Genetic polymorphisms of enzymatic systems, cytokines and growth factors which are 
involved in the process of immunomodulation, inflammation, ECM-turnover and anti-
oxidative stress defense may explain the widely different individual extent of HCV-induced 
graft damage [61]. 
3.6.2.1 Transforming growth factor-β1 (TGF-β1) 
As a multifunctional polypeptide with fibrogenic, an anti-inflammatory and anti-
proliferative property, TGF-β1 is considered to play a pivotal role in the hepatic fibrogenesis 
strongly upregulating the production and deposition of ECM-components [10, 17, 62]. 
Similarly to the natural setting of HCV-infection, functionally relevant polymorphisms of 
TGF-β1 at codon 25 are associated with the rapid development of HCV-induced graft 
fibrosis. 
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codon-25 genotypes and max. F-stages (p<0.001)
 
Fig. 4. Genotype distribution (TGF-β1) within maximal fibrosis stages 
C-allele of the TGF-β1-gene (codon 25) has been identified as marker for graft fibrosis 
development and was observed significantly less frequently in advanced fibrosis stages 
compared to lower ones (fig. 4; p=0.001) [63]. 
3.6.2.2 Interleukine-28B (IL-28B) 
According to numerous studies, genetic variants of IL-28B seem to be significantly involved 
in the pathogenesis of HCV-related graft inflammation and antiviral therapy response [60, 
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64, 65]. IL-28B-gene encodes an antiviral protein - IFN-λ with antiviral properties in 
response to IFN-α, and is upregulated by peripheral blood mononuclear cells and 
hepatocytes during HCV-infection [40, 66-68]. Recently, a significant association of IL-28B-
genotype distribution was observed with the median grade of inflammation (p<0.001), mean 
levels of aminotransferases (ALT: p=0.001, AST: p=0.003; fig.5), median pre-treatment 
viremia level within 1 year after LT (p=0.046) and interferon-based antiviral therapy failure 
(p<0.001). IL-28B polymorphism (rs8099917) seems to influence the degree of graft 
inflammation at biochemical and histological levels [64]. 
 
Fig. 5. Levels of aminotransferases according to IL-28B-genotypes 
Among successfully treated patients G-allele was significantly less frequent and GG-
genotype was not present at all [64]. G-allele might serve as a marker for graft inflammation 
and as predictor for unfavorable antiviral therapy outcome in HCV-re-infected LT-
population [60, 64]. 
The identification of non-invasive inflammation and fibrosis markers might help to 
differentiate re-infected patients with stable graft function without significant inflammation 
or fibrosis progression from patients at risk for short-term graft damage and define the 
indication for antiviral treatment. 
3.7 Organ allocation system 
Methodological changes in the principals of graft allocation may affect the course of HCV-
associated graft disease. Since December 2006 liver graft allocation has been carried out 
according to MELD-score, which primarily assesses the impairment of liver function and 
secondarily reflects the extent of kidney damage. Some evidence arises about the negative 
impact of the current allocation system regarding survival, rate of re-transplantation, 
fibrosis progression and success of antiviral treatment. Therefore, the MELD-score, as an 
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apparently reasonable attempt to improve the procedure of organ distribution, must 
undergo a critical analysis in future. 
4. Antiviral therapy 
The indication for HCV-treatment after LT depends on the individual clinical and biochemical 
condition after a definitive stabilization of the graft function, which is usually achieved 
within six post-operative months [69]. Analogously to the natural setting, therapy regimen 
is based on the administration of pegylated interferon-α2a (Peg-IFN-α2a) and ribavirin 
(RBV) for 12-18 months. Interferons are natural proteins with antiviral, antiproliferative and 
immunomodulatory features. They are responsible for the intracellular RNA-degradation 
and the inhibition of RNA-translation. Among all known interferons (IFN-α, IFN-β, Peg-
IFN-α2b), pegylated IFN-α2a seems to have the highest antiviral potency, though similar to 
Peg-IFN-α2b, demonstrating superior treatment results in patients with HCV-re-infection 
[19, 70-75]. Attenuation of renal clearance and improved biochemical stability may explain 
prolonged half-time and therapeutical advantages observed. Ribavirin inhibits 
inosinmonophosphate-dehydrogenase and reduces the intracellular concentration of 
guanosin. RBV-monotherapy may significantly decrease the HCV-load (1 log step). 
For a better comparability of results, the treatment outcome has been divided into widely 
accepted terms: end of treatment response (ETR: HCV-negativity at the end of treatment), 
sustained virologic response (SVR: HCV-RNA-negativity 6 months after therapy 
completion), relapse (detectable HCV-RNA after therapy completion), breakthrough 
(detectable HCV-RNA during treatment after initial therapy response) and non-response 
(persistent HCV-load under treatment). SVR before transplantation is observed in 50% of all 
treated cases with HCV-genotype-1 and in 80% with genotypes 2-3 [74]. As long as IFN-
α remains the backbone of antiviral therapy, the identification of predictors for the therapy 
outcome is crucial. 50% of graft recipients survive 10 years without any significant fibrosis 
progression and in some cases even without antiviral treatment (own data, Charité, Berlin, 
Berlin). Therefore, unnecessary exposition to adverse therapy events in non-responders 
could be avoided by improved predictability. HCV-genotype and early viral kinetics are 
predominantly considered to be important for therapy performance and its potential 
modification [69, 76]. Apart from the identified factors (high levels of immunosuppression, 
corticosteroid-based ACR-treatment and HCV-genotype-1b), unfavorable host- and donor-
related genetic confounders are suspected to exert a negative influence on the course and 
success of antiviral treatment [22, 69, 77]. According to several studies, genetic variants of 
IL-28B are strongly considered to affect the antiviral therapy results [64, 78, 79]. Along with 
other accepted predictive parameters, IL-28B-genotyping may be a useful diagnostic 
instrument for the indication and performance of antiviral therapy before and after LT [52, 
60, 78, 80]. 
4.1 Current treatment standards 
The aim of antiviral treatment implies the reduction or complete HCV-clearance as 
responsible noxious agent in the development of HCV-associated graft disease. In spite of 
low success rates, HCV-infection is treated by subcutaneous administration of 180μg of Peg-
IFN-α2a once a week and oral intake of RBV up to three times per day [22, 35, 81]. The 
cumulative duration of antiviral treatment comprises 12-18 months.  
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The major advantage of peg-interferon α2a and ribavirin-therapy consists in the summation 
of the antiviral potency. However, bone marrow toxicity, psychiatric disorders and rejection 
frequently limit therapy success. Due to high rates of predominantly hematological adverse 
events (anemia, leucopenia) and a significant risk of graft decompensation, antiviral 
treatment should be performed under a close patient monitoring. Myelotoxic effect of IFN 
results in the suppression of granulocytes and thrombocytes, whereas RBV induces anemia 
[77, 82]. Therapeutical support of hematological and mental disorders may frequently be 
necessary. Frequently observed anemia may result in the reduction of the RBV-dose or in 
the administration of erythropoietin. Leucopenia may require a dose reduction of IFN or 
administration of granulocyte stimulating growth factors. Mood disorders may be handled 
by antidepressants or social support. While performing a strenuous, expensive and 
frequently futile effort of virus elimination, 60-70% of transplants with HCV-graft hepatitis 
are treated without sustained virologic response [72]. 
4.2 Alternative strategies 
Demonstrating poor treatment results and serious adverse events of IFN-based therapy, 
reasonable alternative treatment options are needed to complement or to replace the 
standard therapeutical approach. Silibinin experiences its renaissance in the treatment of 
chronic liver diseases although it has been known for years as hepatoprotective herbal and 
used by patients suffering from chronic liver disease of various causes [83-85]. In contrast to 
unclear antiviral efficacy of oral silibinin treatment, according to the results of published 
studies, a significant antiviral effect could be observed after intravenous administration of 
silibinin [84, 86-90]. Next to three other flavonolignan isomers (isosilybin, sylidianin and 
silychristin) silibinin is the most pharmacologically active component of silybum marianum 
and has been shown to improve biochemical markers of liver function and symptoms in a 
range of conditions including acute and chronic viral hepatitis, alcoholic liver disease and 
drug-related liver injury [83, 91-94]. As a potent free radical scavenger, silibinin has been 
shown to reduce the initiation of pathogenetically important lipid peroxidation and to lower 
HCV-RNA-load [92, 95, 96]. The substance exerts a direct antiviral effect on the HCV-
replicon system inhibiting RNA-dependant HCV-polymerase. Furthermore, silibinin has 
been shown to affect the major actors in scar tissue formation suppressing TGF-β1-synthesis 
and HSC-activity [92, 97, 98]. 
The evidence of antiviral efficacy of silibinin in patients with HCV-related liver damage is 
limited due to a paucity of representative clinical trials, in spite of its popularity among 
patients suffering from various chronic liver diseases [92, 99]. Recent reports have 
demonstrated significant antiviral properties of intravenously administered silibinin in IFN-
non-responders in the natural setting of HCV-infection, convincingly suggesting a dose- and 
treatment duration-dependent antiviral effect [92]. Several observations based on 
unfortunately low sample size cohorts, demonstrated that intravenous administration of 
silibinin after LT may be an effective therapeutic approach in the treatment of HCV-re-
infection, even in non-responders to IFN-based therapy [99, 100]. Rapid normalization of 
aminotransferases and an exponential decline of HCV-load during silibinin treatment have 
been reported (fig. 6) [100]. Moreover, sustained viral elimination may apparently occur 
even after treatment with silibinin, only. Interestingly, in patients treated directly after LT, 
no significant antiviral effect could be observed, probably due to initially high levels of 
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immunosuppression (unpublished data, Charité, Berlin). Although no large scale studies 
have been carried out yet, silibinin might be an effective therapeutic approach in the 
treatment of HCV-re-infection and should be evaluated further. Any kind of antiviral 
supplementation to current therapy regimen should be welcome in the age of donor organ 
shortage to strengthen current antiviral therapy regimen and to avoid graft loss with 
subsequent re-transplantation. 
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Fig. 6. HCV-load during silibinin treatment after LT 
Randomized, placebo-controlled clinical trials with a representative number of graft 
recipients suffering from HCV-re-infection are needed to definitely answer the question of 
the efficacy of intravenous silybium marianum solution and its antiviral potential. As long 
as IFN-α remains the backbone of antiviral therapy, the identification of predictors for 
therapy outcome is crucial. Regarding potential therapy success, frequent severe adverse 
events of IFN-RBV-therapy are commonly accepted. An unnecessary exposition to adverse 
therapy events in non-responders could thus be avoided by an improved predictability. 
4.3 Re-transplantation 
Re-transplantation is frequently required (up to 10%) in patients with HCV-related graft 
cirrhosis as the only option of treatment [12, 15]. Significantly decreased survival rates after 
re-transplantation compared to first LT are in the center of scientific attention and long-term 
outcome has been reported to be inferior to other indications [3, 11, 39]. Physical condition, 
MELD-score, technical obstacles and antiviral therapy response are currently accepted as 
predictors for graft and patient survival after re-LT [39, 101]. 
5. Summary and future prospective 
As long as HCV-recurrence exists as currently inevitable phenomenon, HCV will continue 
to endanger the success of LT. While performing a strenuous, expensive and frequently 
futile effort of interferon-based virus elimination, 60-70% of graft recipients are still treated 
without achieving SVR, thus leaving overall poor results. The natural course of HCV-
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recurrence is not uniform and is influenced by a whole variety of factors. Therefore, the 
identification of non-invasive inflammation and fibrosis markers might help to differentiate 
re-infected patients with stable graft function without significant inflammation or fibrosis 
progression from patients at risk for short-term graft damage and define the indication for 
antiviral treatment. Moreover, it is indispensable to identify patients who are likely to 
respond to IFN-based antiviral treatment. The individual variability of disease development 
may be divided roughly into three different patient groups (A: no fibrosis progression, B: 
treatable progression and C: untreatable progression of graft dysfunction). The indication 
for antiviral therapy in group B seems to be more urgent in contrast to group A, which may 
stay stable for several years regarding their graft function, thus avoiding possibly 
unnecessary exposition to pharmaceutical side effects. Group-C- patients, as high risk 
patients may require treatment adjustment regarding its intensity, duration and mode 
including alternative therapeutical strategies. 
Although HCV-recurrence represents an inevitable post-transplant phenomenon, the 
development of advanced fibrosis stages is highly variable or even individual. Furthermore, 
the outcome of antiviral treatment seems to depend on multiple factors, too. In spite of 
recent advances in HCV-graft-hepatitis treatment, prediction of therapy response and risk 
stratification in graft fibrosis progression, a further extensive investigation is still required. 
Improvement in prevention, prediction of disease course, individualized antiviral treatment 
and alternative antiviral medication may help to increase survival rates after LT for an HCV-
associated graft disease. 
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